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Abstract Peroxynitrite stimulated the synthesis of cyclic GMP 
by rat aortic smooth muscle in a time- and dose-dependent man- 
ner. Peak formation of cyclic GMP occurred at 1 rain with 100 
/~M peroxynitrite and was inhibited by oxyhemoglobin. Peroxyni- 
trite was less potent than nitric oxide in stimulating cyclic GMP 
synthesis. Peroxynitrite also enhanced endothelial-dependent cy- 
clic GMP synthesis, via generation of a long-lived substance, 
which was prevented by inhibition of glutathione synthesis. These 
data show that peroxynitrite stimulates cyclic GMP synthesis, 
inferring production of low yields of nitric oxide or associated 
derivatives. Additionally, vascular exposure to peroxynitrite po- 
tentiates endothelial-dependent activation of guanylate cyclase. 
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I. Introduction 
It has been recognized for several years that the vasoactive 
properties of nitric oxide (.NO) are diminished by superoxide 
anion (02-) [1,2]. The rapid reaction o f 'NO with 0"2- is almost 
diffusion-limited in rate (k= 6.7× 109 M- l ' s  -I) [3], forming 
peroxynitrite anion. Peroxynitrite is a potent oxidant that di- 
rectly oxidizes a wide spectrum of biological molecules, such as 
DNA constituents [4], lipids [5], and amino acids [6]. Alterna- 
tively, peroxynitrite can be protonated to peroxynitrous acid 
(ONOOH), yielding a product with hydroxyl radical (° OH)-like 
activity and nitrogen dioxide ('NO2) [4,7]. 
It is unclear whether the inhibitory effects of 0"2- on -NO- 
mediated vasodilation are due to decreased steady state concen- 
trations o f .NO available to activate vascular soluble guanylate 
cyclase, the direct inhibition ofguanylate cyclase activity, or the 
generation of a product with less potent guanylate cyclase acti- 
vating properties. Paradoxically, recent reports have noted that 
peroxynitrite causes vasodilation both in endothelium-intact 
coronary artery and endothelium-denuded pulmonary artery 
[8,9], possibly by formation of S-nitroso derivatives. The pur- 
pose of the present study is to examine the influence of per- 
oxynitrite on cGMP production by cultured rat aortic smooth 
muscle cells (RASM) and its effects on endothelial-dependent 
increases in cGMP synthesis by a reporter cell, RFL-6 fibro- 
blasts [10]. It is concluded that while peroxynitrite is a less 
potent activator of cGMP synthesis than ,NO, peroxynitrite 
can enhance ndothelial-dependent production of cGMP in a 
thiol- dependent fashion. 
2. Materials and methods 
2.1. Cell culture 
Rat aortic smooth muscle cells were isolated and cultured as de- 
scribed previously [11]. Briefly, cells were grown in 21% 02, 5% CO2 
at 37°C in Dulbecco's Modified Eagle Media supplemented with 10% 
newborn calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 
,ug/ml streptomycin on collagen-coated plates. Cells were subcultured 
at a split ratio of 1:4, fed twice weekly, and used within 24 h of 
confluency. Experiments were performed with RASM between passage 
4 and passage 10. Smooth muscle cells were routinely identified by the 
presence of smooth muscle ~-actin. Bovine aortic endothelial cells 
(BAEC) were cultured in M199 with 5% newborn calf serum, 5% iron- 
supplemented calf serum and antibiotics as described above. Experi- 
ments were carried out on passage 5 to passage 10 cells within 36 h of 
confluency. The purity of BAEC cultures was determined on the basis 
of their characteristic cobblestone morphology, positive immunostain- 
ing for factor VIII antigen and selective incorporation of fluorescently 
labeled acetylated-LDL. The rat lung fibroblast line, RFL-6 (ATCC, 
CCL192; Rockville, MD) was grown in Kaighn's F-12 media (Irvine 
Scientific, Santa Ana, CA) supplemented with 10% calf serum, penicil- 
lin and streptomycin. Cells were subcultured at a split ratio of I : 3, fed 
three times weekly, and used within 24 h of confluency. Cells between 
passage 12 and passage 20 were used. 
2.2. Peroxynitrite synthesis 
Peroxynitrite was synthesized as previously described [4], with con- 
centrations determined spectrophotometrically (e302 = 1670 M i. cm ~) 
[12]. Working solutions of peroxynitrite were prepared by dilution in 
0.1 N NaOH and used within 15 min. 
2.3. Preparation of nitric oxide 
Saturated solutions of °NO were prepared by equilibrating -NO gas 
(Matheson) in vacuum containers containing argon-saturated phos- 
phate-buffered saline, pH 7.4 (PBS): 140 mM NaC1, 0.9 mM CaCI2, 0.5 
mM MgCI> 2.7 mM KC1; 1.5 mM KH2PO4, 8.1 mM Na2HPO 4. The 
concentration f °NO was determined by oxidation of oxyhemoglobin 
(HbO2) to methemoglobin [13] and ranged from 1.6 to 1.7 raM. Oxyhe- 
moglobin was prepared by sodium dithionite reduction of methemo- 
globin. Dithionite was removed by dialysis in distilled H20 and HbO2 
concentration determined spectrophotometrically [14]. For cell treat- 
ments, aliquots of .NO-containing buffer were removed via gas-tight 
syringes, diluted in de-gassed PBS as necessary, and added to RASM 
cells within 5 s, a time period observed to not affect dissolved .NO 
concentration. 
*Corresponding author. Fax: (1) (205) 934-7437. 
Abbreviations." BAEC, bovine aortic endothelial cells; BSO, buthionine 
sulfoximine; cGMP, cyclic GMP; • OH, hydroxyl radical; IBMX, isobu- 
tylmethylxanthine; -NO, nitric oxide; NO3, nitrate; NO2, nitrite; -NO,, 
nitrogen dioxide; HbO2, oxyhemoglobin; ONOOH, peroxynitrous acid; 
PBS, phosphate-buffered saline; RASM, rat aortic smooth muscle cells; 
SNP, sodium nitroprusside; 0"2, superoxide; SOD, superoxide dis- 
mutase. 
2.4. Cyclic GMP quantitation 
Confluent RASM, grown on 35-mm dishes, were washed three times 
with PBS. All experiments were carried out in 1.0 ml of PBS in the 
presence of isobutylmethylxanthine (IBMX; 100 #M). Sodium nitro- 
prusside (SNP; 1 ,uM) was included as a positive control for soluble 
guanylatc yclase activation. Peroxynitrite was added to cells at the 
concentrations and times specified. Control cells were treated with a 
volume of 0.1 N NaOH equivalent to that added during peroxynitrite 
treatment of cells. Separate studies howed no change in pH or cGMP 
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levels from untreated cells. For cell cGMP analyses, the buffer was 
removed and 0.5 ml of 6% TCA added for 30 min. Acid extracts were 
transferred to microcentrifuge tubes and centrifuged at 8000 x g × 5 
min. Supernatants were extracted 3 times with H20-saturated ther; the 
solvent evaporated with a stream of N2, and extracts resuspended in 
50 mM sodium acetate, pH 6.2, and stored at -20°C until assayed for 
cGMP by ELISA (Cayman Chemical, Ann Arbor, MI). Cell pellets 
were resuspended in 0.1 N NaOH and analyzed for protein content [15]. 
2.5. Endothelial cell studies 
Confluent BAEC were rinsed three times with and maintained in 
PBS. Bradykinin (100 nM) and/or peroxynitrite (100 ,uM) were added 
to cells for 3 min in a 1.0 ml final volume. Control cells were treated 
with an equal volume of 0.1 N NaOH. The supernatant was immedi- 
ately transferred to 100/IM IBMX-treated RFL-6 cells and incubated 
for an additional 2 min. Preliminary experiments demonstrated that 
these were optimal concentrations and times for detection of bradyki- 
nin-enhanced cGMP synthesis in RFL-6 cells. Cells were then analyzed 
for cGMP and protein content as described for RASM. In some exper- 
iments, endothelial monolayers were pre-treated for 24 h with 200/~M 
buthionine sulfoximine (BSO) to inhibit glutathione synthesis [16]. Cell 
glutathione content was measured according to the method of Murphy 
et al. [17]. 
2.6. Chemicals and reagents 
Fetal calf serum and iron-supplemented calf serum were from 
Hyclone, Logan, UT. Cell culture reagents were from Gibco, Grand 
Island, NY. Superoxide dismutase was obtained from Diagnostic Data 
Inc., Mountain View, CA. All other chemicals were purchased from 
Sigma, St. Louis, MO. 
2.7. Statistical analysis 
Data was analyzed by one-way analysis of variance, followed by 
post-hoc application of Bonferroni's test. 
3. Results 
3.1. Peroxynitrite and "NO stimulation of smooth muscle cell 
guanylate cyclase 
The time course of peroxynitrite stimulation of cGMP pro- 
duction in RASM showed cGMP concentrations rose within 
15 s of addition of 100/IM peroxynitrite, remained elevated for 
at least 2 min and returned to basal levels within 5 min follow- 
ing addition of peroxynitrite (Fig. 1). Dose-response analysis 
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Fig. 1. Time course of peroxynitrite-induced GMP synthesis in rat 
aortic smooth muscle cells. Following pretreatment with 100 ,uM 
1BMX, RASM were exposed to 100/.tM peroxynitrite, the media re- 
moved and the cells analyzed for cGMP content at the times indicated. 
Data are the mean + S.D. of 3 experiments, each performed in dupli- 
cate. *P < 0.05 compared to 0 time. 
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Table 1 
Effect of ONOO- on rat aortic smooth muscle cell cGMP synthesis 
Condition pmol cGMP/mg cell protein 
Control 2.24 + 0.69 
ONOO- 10.80 + 2.22* 
NO2/NO 3 3.69 _+ 0.64 
ONOO- + HbO2 4.22 _+ 0.90 
SNP 13.69 + 3.97* 
SNP + ONOO- 23.18 +_ 3.35 ÷ 
Following pretreatment with 100 ~M IBMX with or without 2 JIM 
HbO2, cells were incubated for 1 min with 100/IM peroxynitrite or an 
equal volume of decomposed peroxynitrite. To study the effect of per- 
oxynitrite on SNP-stimulated cGMP formation, cells were exposed to 
1 ,uM SNP for 10 min; parallel cultures were treated with 1 tim SNP 
with 100 /IM peroxynitrite added in the final min. Data are 
mean + S.D. of 3 experiments carried out in triplicate. 
*P < 0.05; *P < 0.01. 
revealed the minimum concentration of peroxynitrite that en- 
hanced cGMP synthesis to be 1/IM, with a maximal effect at 
100/~M. This contrasts with the dose-response curve of cGMP 
synthesis timulated by .NO, where threshold stimulation of 
cGMP synthesis occurs at 10 nM, with a maximal effect at 
1/.tM. Peak cGMP levels achieved for peroxynitrite-stimulated 
cells was about 30% of those for -NO-stimulated cells (Fig. 2). 
At physiologic pH, peroxynitrite rapidly decomposes in 
buffer to stable products, principally nitrate (NO3), small 
amounts of nitrite (NO~), with residual contaminating NaCI, 
NaOH and H202. TO determine if the increased cell cGMP 
synthesis was the result of direct peroxynitrite reaction or sec- 
ondary to production of breakdown products, RASM were 
incubated with 100/IM peroxynitrite, or to an equal volume of 
decomposed peroxynitrite. There was no significant enhance- 
ment of cGMP synthesis induced by peroxynitrite decomposi- 
tion products while direct addition of peroxynitrite stimulated 
cGMP production 5-fold. Addition of 2 / IM  HbO 2 prevented 
the peroxynitrite-induced increase in cGMP (Table 1). 
To ascertain if peroxynitrite inhibited guanylate cyclase ac- 
tivity, the effect of peroxynitrite on SNP-mediated formation 
of cGMP was studied. Peroxynitrite nhanced SNP-induced 
stimulation o fcGMP production by RASM. A 10 min incuba- 
tion with 1 /.tM SNP increased RASM production of cGMP 
6-fold. The addition of 100/IM peroxynitrite to cell reaction 
systems doubled SNP-induced cGMP synthesis (Tables 1 
and 2). 
3.2. Peroxynitrite stimulation of  endothelial cell-dependent 
cGMP synthesis by RFL-6 cells 
Direct exposure of RFL-6 cells to 100 ~M peroxynitrite for 
2 rain caused a doubling of cGMP levels over control (control, 
2.01 + 0.18 pmol cGMP/mg protein; 2 rain, 4.14 + 0.28 pmol 
cGMP/mg protein; P < 0.05); when the incubation period was 
increased to 5 rain (the total time period of the BAEC-RFL-6 
incubations), cGMP levels were no longer increased (5 min, 
2.32 + 0.22 pmol cGMP/mg protein). Cyclic GMP production 
by the lung fibroblast cell line, RFL-6, increased 100% over 
controls when incubated for 2 min with media transferred from 
BAEC, presumably due to the constitutive release of .NO by 
endothelial cells. Incubation of BAEC with 100 nM bradykinin 
for 3 min resulted in a 3-fold increase in RFL-6 cGMP content, 
while BAEC exposure to 100/.tM peroxynitrite also induced a 
3-fold increase in RFL-6 generation of cGMP. Co-incubation 
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Fig. 2. Dose response of nitric oxide- and peroxynitrite-induced cGMP 
synthesis in rat aortic smooth muscle cells. Cells, pre-treated with 100 
/IM IBMX, were incubated with • NO or peroxynitrite. At 1 rain, the 
media was removed, and the cells were analyzed for cGMP content. 
Data are the mean + S.D. of 3 experiments, each performed in tripli- 
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Fig. 3. Effect of peroxynitrite on endothelial cell-dependent cGMP 
synthesis in RFL-6 cells. Confluent BAEC in 35 mm dishes were treated 
for 3 rain with 100 nM bradykinin and/or 100/.tM peroxynitrite. The 
media was then transferred toIBMX treated RFL-6 cells and incubated 
for 2 rain before analyzing for cGMP. Filled bars represent control 
RFL-6 cells. Hatched bars represent RFL-6 cells treated with 10 ,uM 
HbO2 in addition to IBMX. Data are the mean + S.D. of 4 experiments, 
each performed in triplicate. *P < 0.05 compared to control; *P < 0.05 
compared to bradykinin. 
of BAEC with bradykinin and peroxynitrite l d to an 8-fold 
increase in RFL-6 cGMP content (Fig. 3). Addition of 10 ~M 
HbO2 to the medium of RFL-6 cells prevented the rise in 
BAEC-stimulated RFL-6 cGMP levels in all treatments. When 
the incubation period was increased from 3 to 10 min, there was 
no significant change in the effects of either bradykinin or 
peroxynitrite on RFL-6 cGMP synthesis. However, there was 
a significant decrease in cGMP formation following co-incuba- 
tion of BAEC with peroxynitrite and bradykinin for 10 min 
before transfer of medium to RFL-6 cells (Table 1). When 
BAEC were treated for 24 h with 200 /~M BSO to inhibit 
glutathione synthesis, cGMP formation following co-incuba- 
tion with peroxynitrite and bradykinin was also diminished 
(Fig. 4). Control cell glutathione content was 20 + 2.1/~mol/mg 
protein. The glutathione content in BSO-treated cells was 
below the sensitivity of assay detection. There was no effect of 
100/.tM NO~ or decomposed 100/.tM peroxynitrite on RFL-6 
cGMP content, either when first added to BAEC and the media 
then transferred to RFL-6 cells or when added directly to RFL- 
6 cells (data not shown). 
4. Discussion 
Nitric oxide is constitutively s nthesized by the oxidation of 
L-arginine in endothelial cells and neural tissue. Nitric oxide is 
also generated in large amounts by numerous cell types upon 
exposure to inflammatory stimuli such as lipopolysaccharide 
and cytokines, following the expression of inducible ,NO syn- 
thase [18]. The effects of -NO on vessel tone are related to heme 
iron binding and subsequent activation of soluble guanylate 
cyclase, formation o fcGMP and relaxation of vascular smooth 
muscle. The vasoactive properties of -NO are diminished in the 
presence of 0"2- [1,2,19] with the radical-radical reaction of .NO 
with O'2- occurring at near diffusion-limited rates: 6.7 × 10 9 
M-J.s - '  [3]. Since the rate constant for O'2- scavenging 
by SOD is 2 × l09 M -1. s -~, the facile reaction o f .NO reaction 
with O':- effectively competes with the dismutation of O'2- by 
SOD. It was not clear if this interaction of .NO with 0"2- leads 
to the formation of a compound that directly inhibits the pro- 
duction of cGMP or whether peroxynitrite formation merely 
decreases the concentration o f -NO available to activate 
guanylate cyclase. Thus, the aims of this study were to evaluate 
the direct effect of peroxynitrite on vascular smooth muscle 
cGMP formation and the effect of peroxynitrite on endothelial- 
dependent guanylate cyclase activation. 
Direct exposure of vascular smooth muscle, maintained in a 
protein- and thiol-free buffer, to peroxynitrite results in a lim- 
ited stimulation of cGMP synthesis. The increase in cGMP 
following exposure to peroxynitrite was much less than that 
achieved with equimolar amounts o f -NO,  with the precise 
proximal chemical species causing stimulation of vascular 
smooth muscle cell guanylate cyclase unclear. The increase in 
cGMP was not due to the stable decomposition products of 
peroxynitrite, NO~ and NO3, as these species did not result in 
stimulation of RASM guanylate cyclase activity at the con- 
centrations employed. The ability of HbO 2 to attenuate per- 
oxynitrite stimulation of cGMP synthesis uggests that per- 
oxynitrite nhancement of guanylate cyclase activity was ,NO 
mediated [20]. This data concurs with the recent report of 
peroxynitrite-induced relaxation in isolated endothelium- 
Table 2 
Endothelial-dependent cGMP synthesis 
Condition % Control cGMP 
RFL-6 100 ± 10 
ONOO- 3 min 280 + 18 
10 min 214 + 39 
BK 3 min 280 + 80 
10 min 215 + 48 
ONOO- + BK 3 min 771 + 100 
10 min 310 + 104" 
Confluent BAEC in 35 mm dishes were treated for 3 or 10 min with 100 
nM bradykinin and/or 100/.tM peroxynitrite. The media was then 
transferred to IBMX-treated RFL-6 cells and incubated for 2 rain 
before analyzing for cGME Data are mean + S D. of 3 experiments 
performed in triplicate *P < 0.05 compared to 3 min 
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Fig. 4. Effect of buthionine sulfoximine on endothelial cell-dependent cGMP synthesis n RFL-6 cells. Confluent BAEC in 35 mm dishes were treated 
for 3 rain with 100 nM bradykinin and/or 100 HM peroxynitrite. The media was then transferred to IBMX treated RFL-6 cells and incubated for 
2 rain before analyzing for cGMP. Open bar represents basal RFL-6 cGMP content. Filled bars represent control BAEC. Hatched bars represent 
BAEC treated with 200 pM BSO for 24 h. Data are the mean + S.D. of 3 experiments, each performed in triplicate. *P < 0.05 compared to 
non-BSO-treated BAECs. 
denuded bovine pulmonary arterial rings [8]. Auto-oxidation of
peroxynitrite can result in the formation of approximately 
0.25% "NO [20]; thus the bolus addition of 100/IM peroxyni- 
trite could generate as much as 40 nM -NO. While peroxynitrite 
will directly, albeit minimally, react with HbO2 [21], the reaction 
of .NO with HbO2 can be almost quantitative. The addition of 
2/ IM HbO2 completely prevented the rise in cGMP following 
treatment with 100/~M peroxynitrite, suggesting that "NO was 
responsible for the stimulation of guanylate cyclase. Moreover, 
the importance of this direct reaction of peroxynitrite with 
HbO2 at physiologic pH is unclear as the reaction rate is mark- 
edly diminished under non-alkaline conditions [21 ]. In addition 
to its direct effect on cGMP production in RASM, peroxyni- 
trite enhanced cGMP synthesis that was stimulated by a .NO 
donor, SNP. Such an effect on cGMP synthesis does not sug- 
gest that peroxynitrite inhibits guanylate cyclase activity. 
While peroxynitrite was a weak stimulant of smooth muscle 
cell cGMP formation, exposure of endothelial cells to peroxyni- 
trite generated a long-lived substance that, when transferred to 
reporter cells, enhanced cGMP production in an oxyhemo- 
globin-inhibitable manner. It is improbable that peroxynitrite 
directly stimulated RFL-6 generation of cGMP, because the 
3 rain exposure of endothelial cells to peroxynitrite also results 
in complete decomposition of peroxynitrite before transfer of 
the supernatant to the reporter cells. While 2 min incubation 
of RFL-6 with peroxynitrite increased cGMP 2-fold, extending 
the incubation period to 5 min resulted in a return to control 
levels. Also, neither 100/IM NO~ nor decomposed peroxynitrite 
was capable of increasing RFL-6 synthesis of cGMP. Potential 
candidates for more long-lived substances that could stimulate 
endothelial-dependent RFL-6 cGMP synthesis include S-nitro- 
soglutathione or other reversibly S-nitrosated intermediates ca- 
pable of activation of guanylate cyclase [8,22,23]. The concept 
of cellular thiols serving as intermediates in "NO transport is 
additionally supported by the 40% decrease in peroxynitrite- 
treated endothelial-dependent cGMP formation, following de- 
pletion of endothelial glutathione by treatment with BSO. 
Numerous pathophysiologic processes uch as sepsis, is- 
chemia-reperfusion injury, or acute inflammation are associ- 
ated with enhanced production of both O'2- and .NO, with these 
species derived from either the same or different cell types to 
yield peroxynitrite intracellularly, intravascularly or in extracel- 
lular compartments. It has been estimated that local production 
of peroxynitrite could reach 1 mM.min -~ following macro- 
phage activation [24]. We have demonstrated that peroxynitrite 
stimulates cGMP production by vascular smooth muscle cells, 
although to a lesser extent than authentic .NO. In addition, 
peroxynitrite also enhances endothelial-dependent cGMP pro- 
duction. Since peroxynitrite induces vasorelaxation f both cor- 
onary and pulmonary artery rings [8,9] and inhibits platelet 
function [25], it is concluded from the observations reported 
herein that these effects are at least partially mediated by acti- 
vation of guanylate cyclase. However, these studies do not 
address the target molecule reactivities of peroxynitrite owards 
vascular structural and functional components that are not 
cGMP-mediated. Thus, peroxynitrite or its secondary reactive 
and potentially cytotoxic products are likely to contribute as 
yet undefined roles in the alteration of vascular eactivity asso- 
ciated with enhanced production of "NO and O~-. 
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